Interní Med. 2005; 7(1): 7-9

Primární prevence náhlé srdeční smrti

MUDr. Lubomír Křivan Ph.D
Interní kardiologická klinika FN a LF MU v Brně

Keywords: sudden cardiac death, implantable cardioverter defibrillator, primary prevention.

Published: December 31, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Křivan L. Primární prevence náhlé srdeční smrti. Interní Med. 2005;7(1):7-9.

Náhlá srdeční smrt je v 85% způsobena maligní arytmií. Prevence náhlé smrti u pacientů, kteří dosud maligní arytmii neprodělali, je v současnosti u rizikových jedinců zajišťována implantací kardioverterů-defibrilátorů. Článek pojednává o současných možnostech rizikové stratifikace nemocných s ischemickou chorobou srdeční, dilatující kardiomyopatií, srdečním selháním a některými vzácnějšími srdečními chorobami.

Primary prevention of sudden cardiac death

Malignant ventricular arrhythmias are responsible for sudden cardiac death in 85% of cases. Implantable cardioverters-defibrillators are used for sudden death prevention also in patients at high risk, without a previous history of a malignant arrhythmia. The article describes current risk stratification methods in patients with coronary artery disease, dilated cardiomyopathy, chronic heart failure and some less common cardiac diseases.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anderson JL, Hallstrom AP, Epstein AE. for the AVID investigators. Design and results of the Antiarrhythmic versus implantable defibrillators registry. Circulation 1999; 99: 1692-1699. Go to original source... Go to PubMed...
    2. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idipathic dilated cardiomyopathy. The cardiomypathy trial (CAT). Circulation 2002; 105: 1453-1458. Go to original source... Go to PubMed...
    3. Bigger JT. Why patients with congestive heart failure die: Arrhythmias and sudden cardiac death, Circulation 1987; 75: IV28-IV35.
    4. Bytešník J. Stratifikace rizika náhlé arytmické smrti a možnosti nefarmakologické léčby komorových arytmií. Kapitola 3 v: Kolbel F. Trendy soudobé kardiologie, Galén 1999: 24-40.
    5. Corrado D, Basso Ch, Nava A, et al. Arrhythmogenic right ventricular cardiomyopathy: Current diagnostic and management strategies. Cardiology in review 2001; 9 (5): 259-265. Go to original source... Go to PubMed...
    6. Huikuri Heikki V, Castellanos Augustin, Myerburg Robert. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345, 20: 1473-1482. Go to original source... Go to PubMed...
    7. Josephson M, Hein J, Wellens J. Implantable defibrillators and sudden cardiac death. Circulation 2004; 109: 2685-2691. Go to original source... Go to PubMed...
    8. Kjekshus J, Arrhythmias and mortality in congestive heart failure, Am J Cardiol 1990; 65: 42I-48I. Go to original source... Go to PubMed...
    9. Knight BP, Bitar CF, Pelosi F, et al. Predictorsof mortality in AMIOVIRT: nonischaemic dilated cardiomyopathy and nonsustained ventricular tachycardia. PACE 2002; 24, PII: 526.
    10. Kozák M. Náhlá srdeční smrt - problém současné kardiologie. Vnitř. lék. 2001, 47; 9: 634-641.
    11. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. Circulation 2000; 102: 748-754. Go to original source... Go to PubMed...
    12. Maron BJ. Risk stratification and prevention of sudden deathin hypertrophic cardiomyopathy. Cardiology in review 2002; 10: 173-181. Go to original source... Go to PubMed...
    13. Moss AJ, Hall WJ, Cannom DS, et al. for the Multicenter automatic defibrillator implantation trial investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-1940. Go to original source... Go to PubMed...
    14. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Eng J Med 2002; 346 (12): 877-883. Go to original source... Go to PubMed...
    15. Myerburg R, Castellanos A. Cardiac arrest and sudden cardiac death. Chapter 26 in: Braunwald Textbook of Heart Disease, 6th edition, 2001. Go to original source...
    16. Pitschner HF, Neuzner J, Himmrich E, Liebrich A, Jung J, Heisel A. Implantable cardioverter-difibrillator therapy: Influence of left ventricular function on long-term results. J Intervent Card Electrophysiol 1997; 1: 211-220. Go to original source... Go to PubMed...
    17. Priori SG, Aliot C, Blomstron-Lundqist L, et al. Task force on sudden cardiac death, European society of cardiology. Summary of recommendations. Europace 2002; 4: 3-18. Go to original source... Go to PubMed...
    18. Saksena S, Madan N. Management of the patient with an implantable cardioverter-difibrillator in the third millennium. Circulation 2002; 106: 2642-2646. Go to original source... Go to PubMed...
    19. Salukhe T, Francis D, Sutton R. Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION)trial terminated early; combined biventricular pacemaker-defibrillators reduce all-cause mortality and hospitaliyation. Int J Cardiol. 2003; 87: 119-120. Go to original source... Go to PubMed...
    20. Sander S, Wieselthale G, Zuckermann A, et al. Survival benefit of implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation. Circulation 2001; 104: I171-176. Go to original source... Go to PubMed...
    21. Táborský M. Zásady pro implantace kardiostimulátorů a implantabilních kardioverterů-defibrilátorů, Cor Vasa 2001: 43 (2): Kardio, K32-K41.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.